Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 2Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Recurrence 1Neoplasm Metastasis 1Lymphatic Abnormalities 1Lymphangioma, Cystic 1Lymphangioma 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1Genetic Diseases, Inborn 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1

Interventions

pembrolizumab 9Cetuximab 5Surveys and Questionnaires 4Cisplatin 4dostarlimab 2abemaciclib 2Standard of Care 2Docetaxel 2Carboplatin 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1toripalimab 1tislelizumab 1tipifarnib 1ribociclib 1repotrectinib 1patritumab deruxtecan 1palbociclib 1olaparib 1nimotuzumab 1monalizumab 1ibrutinib 1fludarabine 1exemestane 1entrectinib 1ebselen 1durvalumab 1disitamab vedotin 1avelumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × Alpelisib × 30 days × Clear all
NCT04997902 2026-06-05

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Kura Oncology, Inc.

Phase 1/2 Completed
45 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡